Clinical Trial: A Phase II Study of Single Tremelimumab with Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/metastatic Combined Hepatocellular-cholangiocarcinoma

U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06855225) titled 'A Phase II Study of Single Tremelimumab with Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/metastatic Combined Hepatocellular-cholangiocarcinoma' on Feb. 25.

Brief Summary: This is a single arm phase 2 study of Single Tremelimumab with Regular Interval Durvalumab (STRIDE) plus Gemcitabine and Cisplatin (GEMCIS) in locally advanced unresectable/metastatic combined hepatocellular-cholangiocarcinoma (cHCC-CCA). Cycles 1 through 8 will be in 3 week intervals and Cycles 9+ will be in 4 week intervals. Tremelimumab is administered at 300mg intravenously once at Cycle 1. Durvalumab is administe...